AstraZeneca shares remain under pressure after trial failure
AstraZeneca shares remain under pressure following disappointing results from a key late-stage clinical trial. In the near term, the company's upcoming quarterly earnings report is likely to be the next major catalyst capable of shifting investor sentiment.
The main negative development for AstraZeneca was the outcome of the Phase III CARDIO-TTRansform trial. The company announced that eplontersen (Wainua) failed to meet its primary endpoint of reducing cardiovascular mortality and hospitalizations in patients with ATTR-CM. Following the announcement, AZN shares fell by more than 6% on July 9.
Despite the market's negative reaction, AstraZeneca's financial position remains solid. A 23.5% return on equity (ROE) and approximately $6.6 billion in free cash flow continue to support the company's long-term investment case.
However, the disappointing CARDIO-TTRansform results are likely to weigh on investor sentiment toward AZN shares for some time.
AstraZeneca could test GBX 12.72–13.00 support
Following the disappointing trial results, AZN shares experienced a sharp decline. Historically, similar gap-down moves have often been followed by additional short-term weakness (highlighted in yellow on the chart).
The nearest support zone lies between GBX 12.72 and GBX 13.00. Given the current market sentiment, this area appears to be the most likely downside target in the short term.
The next major opportunity to change the stock's trajectory will come with AstraZeneca's earnings report on July 27.
Pipeline risks remain in focus for AstraZeneca
Despite the CARDIO-TTRansform setback, AstraZeneca's fundamental outlook remains strong. However, until the company reports earnings on July 27, investor sentiment will likely continue to be shaped by the failed clinical trial and expectations surrounding the future development of its product pipeline.
Latest AstraZeneca News
-
Afghanistan
-
Albania
-
Algeria
-
Angola
-
Argentina
-
Armenia
-
Australia
-
Austria
-
Azerbaijan
-
Bahamas
-
Bahrain
-
Bangladesh
-
Belarus
-
Belgium
-
Bolivia
-
Botswana
-
Brazil
-
Brunei
-
Bulgaria
-
Cambodia
-
Cameroon
-
Canada
-
Chile
-
China
-
Colombia
-
Congo
-
Costa Rica
-
Cote d'Ivoire
-
Croatia
-
Cuba
-
Cyprus
-
Czechia
-
DR Congo
-
Denmark
-
Dominican Republic
-
Ecuador
-
Egypt
-
El Salvador
-
Estonia
-
Eswatini
-
Ethiopia
-
Finland
-
France
-
Georgia
-
Germany
-
Ghana
-
Greece
-
Haiti
-
Hong Kong
-
Hungary
-
India
-
Indonesia
-
Iran, Islamic republic
-
Iraq
-
Ireland
-
Israel
-
Italy
-
Jamaica
-
Japan
-
Jordan
-
Kazakhstan
-
Kenya
-
Korea
-
Kuwait
-
Kyrgyzstan
-
Laos
-
Latvia
-
Lebanon
-
Lesotho
-
Libya
-
Lithuania
-
Luxembourg
-
Madagascar
-
Malaysia
-
Malta
-
Mauritius
-
Mexico
-
Moldova
-
Mongolia
-
Montenegro
-
Morocco
-
Mozambique
-
Myanmar
-
Namibia
-
Nepal
-
Netherlands
-
New Zealand
-
Nigeria
-
North Macedonia
-
Norway
-
Oman
-
Pakistan
-
Palestine
-
Panama
-
Papua New Guinea
-
Paraguay
-
Peru
-
Philippines
-
Poland
-
Portugal
-
Puerto Rico
-
Qatar
-
Reunion
-
Romania
-
Rwanda
-
Saudi Arabia
-
Serbia
-
Singapore
-
Slovakia
-
Slovenia
-
Somalia
-
South Africa
-
Spain
-
Sri Lanka
-
Sweden
-
Switzerland
-
Syria
-
Taiwan
-
Tajikistan
-
Tanzania
-
Thailand
-
Trinidad and Tobago
-
Tunisia
-
Turkey
-
UAE
-
Uganda
-
Ukraine
-
United Kingdom
-
United States
-
Uruguay
-
Uzbekistan
-
Venezuela
-
Vietnam
-
Yemen
-
Zambia
-
Zimbabwe
- Forex
- Crypto
